New presentation on the company's web site dated May 2013.
It shows just how exciting this growth story is.
Built in growth, high barriers to entry, wildly under served market.
Company forecasting $33 mil in adjusted EBITDA, yes, that includes development expense, for calendar 2013. Growing at high teens. Revenue growth high twenties.
Conservatively, if we put a 10 multiple on that I'm coming up with $20 a share and still only trade at 1.7x sales.
If you like Chindex you'll love Novadaq (NVDQ) My share price target in 4 years is $120 minimum, $480 maximum, using only their current products (blood profusion). If their cancer drug is as powerul, you could double those price targets.